Prices Of Formulations Set To Increase From April

New Delhi : Prices of essential medicines – including painkillers, anti-infectives, cardiac drugs and antibiotics – are slated to go up from April, dealing a body blow to consumers already reeling under the impact of inflation.

The government is all set to allow drug companies an increase in line with the change in the annual Wholesale Price Index (WPI). The annual change in WPI, as notified by the government, works out to 12.12% during 2022, the drug prices regulator National Pharmaceutical Pricing Authority (NPPA) said on Monday.

Prices of 384 molecules, which correspond to around 900 formulations across 27 therapies, are expected to go up by over 12%. This is the second year in a row when the increase is more than that allowed for non-scheduled drugs. The 384 molecules, part of the national list of essential medicines, are also known as scheduled drugs, with their prices regulated by the NPPA.

The rest – non-scheduled drugs which are outside price control – are allowed an annual increase of 10% every year. For the year 2021, the subsequent hike in drugs was over 10% in line with change in WPI.

Historically, the increase in prices due to the annual change in WPI has been marginal, ranging between 1% and 2% over the last few years. The NPPA will notify the ceiling prices of the scheduled formulations over the next few days, sources said.

The development will be welcome news for the industry, which has been battling a surge in manufacturing costs on account of multiple factors. During pandemic, the industry was impacted by a rise in prices of raw materials (active pharmaceutical ingredients), freight and increase in plastics and packaging material, among other costs.

“The industry will be relieved once the new prices are notified. It has been facing a cost escalation due to imported raw materials and excipients in certain drugs. Also, it will be a relief for those drugs which were added to the scheduled drugs’ list,” an industry expert said.

  • Related Posts

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    India’s $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face tariffs of 100% from Aug…

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    New Delhi: A joint operation by the Delhi Police Crime Branch, the Central Drugs Standard Control Organisation (CDSCO) and the Gautam Buddha Nagar District Drug Department uncovered a suspected illegal…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

    Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    CDSCO declares 159 drug samples as NSQs in June

    CDSCO declares 159 drug samples as NSQs in June